Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain fog after cancer: can a group program sharpen the mind?

NCT ID NCT07755839

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This pilot trial tests a structured cognitive rehabilitation program called CanCOG® for cancer survivors who experience thinking difficulties—often called 'chemo brain'—after treatment for cancers outside the brain. Sixty adult survivors will be randomly assigned to either the six-week group program or their usual care. The study focuses on whether the program is feasible and acceptable, while also exploring its potential to improve perceived and objective cognitive function, mood, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CanCOG® - a structured cognitive rehabilitation program delivered in small groups over six weekly sessions, combining psychoeducation, cognitive training, and compensatory strategies.
What this could lead to
If effective, this program could offer a practical, non-drug way to help cancer survivors cope with memory, attention, and thinking difficulties, potentially improving daily life and emotional well-being.
What could go wrong
This is a small pilot study focused on feasibility, not proof of benefit. The program may not produce lasting cognitive improvements, and results may not apply to all cancer survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years whose native language is European Portuguese; * Diagnosis of cancer not involving the central nervous system (non-CNS cancer); * Disease stage I to III; * Completion of primary cancer treatment at least 6 months and no more than 5 years prior to enrollment (with the exception of ongoing hormone therapy and immunotherapy); * Score \< 51 on the Perceived Cognitive Abilities subscale of the FACT-Cog v3. Stable psychiatric and neurological medication regimen for at least 3 months prior to enrollment; * Educational level equal to or higher than the 3rd year of primary education; * Ability to read and write in Portuguese and provide informed consent to participate. Exclusion Criteria: * Diagnosis of current severe psychiatric disorders (e.g., schizophrenia, psychosis, bipolar disorder, major depressive disorder, or attention-deficit/hyperactivity disorder); * Diagnosis of communication disorders; * Diagnosis of neurodevelopmental disorders or other severe medical conditions (e.g., history of stroke, encephalitis, dementia or neurodegenerative disease, epilepsy, or traumatic brain injury); * Presence of metastases or other tumors; * History of substance abuse (alcohol or drugs); * Current or prior participation in another cognitive rehabilitation intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer-related cognitive difficulties are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Aveiro

    Aveiro, 3810-193, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.